Olema Pharmaceuticals (Olema Oncology) is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and related hormone-driven cancers. Its lead candidate, palazestrant (OP-1250), is an oral complete estrogen receptor antagonist and selective estrogen receptor degrader in late-stage trials for ER-positive, HER2-negative metastatic breast cancer. The company builds on expertise in endocrine-driven tumors, nuclear receptors, and mechanisms of treatment resistance.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -30.4 | — |
| Q2 2025 | 0 | — | -43.8 | — |
| Q3 2025 | 0 | — | -42.2 | — |
| Q4 2025 | 0 | — | -46.1 | — |
| Q1 2026 | 0 | — | -53.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Rapid7, Inc. (RPD), UP Fintech Holding Limited (TIGR), Ramaco Resources, Inc. (METC), iQIYI, Inc. (IQ), Beta Bionics, Inc. (BBNX), EverQuote, Inc. (EVER)